Trial · NCT02443688
Results by group85
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 85
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Difference From Placebo in Absolute Change From Baseline in Forced Expiratory Volume in 1 Second Percent Predicted (ppFEV1) | 100 mg CTX-4430 | -1.30 | 95% Confidence Interval -3.22 to 0.62 | FEV1 percent predicted | |
| Difference From Placebo in Absolute Change From Baseline in Forced Expiratory Volume in 1 Second Percent Predicted (ppFEV1) | 50 mg CTX-4430 | -3.76 | 95% Confidence Interval -5.65 to -1.86 | FEV1 percent predicted | |
| Difference From Placebo in Absolute Change From Baseline in Forced Expiratory Volume in 1 Second Percent Predicted (ppFEV1) | Pooled CTX-4430 | -2.53 | 95% Confidence Interval -3.88 to -1.18 | FEV1 percent predicted | |
| Difference From Placebo in Absolute Change From Baseline in Forced Expiratory Volume in 1 Second Percent Predicted (ppFEV1) | Matching Placebo | -2.69 | 95% Confidence Interval -4.63 to -0.75 | FEV1 percent predicted | |
| Number of Pulmonary Exacerbations Through 48 Weeks | 100 mg CTX-4430 | 1.57 | 95% Confidence Interval 1.22 to 2.02 | pulmonary exacerbations per year | |
| Number of Pulmonary Exacerbations Through 48 Weeks | 50 mg CTX-4430 | 1.46 | 95% Confidence Interval 1.13 to 1.89 | pulmonary exacerbations per year | |
| Number of Pulmonary Exacerbations Through 48 Weeks | Pooled CTX-4430 | 1.51 | 95% Confidence Interval 1.26 to 1.81 | pulmonary exacerbations per year | |
| Number of Pulmonary Exacerbations Through 48 Weeks | Matching Placebo | 1.56 | 95% Confidence Interval 1.21 to 2.01 | pulmonary exacerbations per year | |
| Hazard Ratio Pulmonary Exacerbation While in the Study | 100 mg CTX-4430 | 0.88 | 95% Confidence Interval 0.576 to 1.339 | hazard ratio | |
| Hazard Ratio Pulmonary Exacerbation While in the Study | 50 mg CTX-4430 | 0.86 | 95% Confidence Interval 0.563 to 1.308 | hazard ratio | |
| Hazard Ratio Pulmonary Exacerbation While in the Study | Pooled CTX-4430 | 0.87 | 95% Confidence Interval 0.605 to 1.246 | hazard ratio | |
| Subjects Without a Pulmonary Exacerbation While in the Study | 100 mg CTX-4430 | 25 | Participants | ||
| Subjects Without a Pulmonary Exacerbation While in the Study | 50 mg CTX-4430 | 26 | Participants | ||
| Subjects Without a Pulmonary Exacerbation While in the Study | Pooled CTX-4430 | 51 | Participants | ||
| Subjects Without a Pulmonary Exacerbation While in the Study | Matching Placebo | 20 | Participants | ||
| Relative Change (Percent Change) From Baseline in ppFEV1 | 100 mg CTX-4430 | -2.38 | 95% Confidence Interval -5.37 to 0.60 | percent change from baseline | |
| Relative Change (Percent Change) From Baseline in ppFEV1 | 50 mg CTX-4430 | -4.81 | 95% Confidence Interval -7.84 to -1.79 | percent change from baseline | |
| Relative Change (Percent Change) From Baseline in ppFEV1 | Pooled CTX-4430 | -3.60 | 95% Confidence Interval -5.72 to -1.47 | percent change from baseline | |
| Relative Change (Percent Change) From Baseline in ppFEV1 | Matching Placebo | -3.40 | 95% Confidence Interval -6.59 to -0.22 | percent change from baseline | |
| Change From Baseline at 48 Weeks for Forced Vital Capacity Percent Predicted (FVC) and FEF25-75% (Forced Expiratory Flow During the Middle Half of the Forced Vital Capacity) Percent Predicted | 100 mg CTX-4430 | Forced vital capacity (FVC) percent predicted | -1.57 | 95% Confidence Interval -3.37 to 0.23 | absolute change of percent predicted |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02443688/results